ANXA5 and neoplasm: Due to the demonstrated potential of AnxA5 as an immune checkpoint inhibitor against PS-mediated immune suppression, we sought to assess the potency of AnxA5 administration as compared to the utilization of other reported immune checkpoint inhibitors by treating TC-1 tumor-bearing C57BL/6 mice that received cisplatin and/or E7 long peptide injection with further administration of AnxA5, anti-TGF-β, anti-PD-1, anti-PD-L1, or anti-TIM-3 (Fig. 4a).